Sinopharm Group Co Ltd
01099: XHKG (HKG)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
HK$29.60 | Sstgnc | Cfjcykk |
Sinopharm's Earnings Slightly Better Than Expected; Shares Still Have Room to Rally
Narrow-moat Sinopharm’s full-year earnings were slightly stronger than our expectation due to better-than-expected resilience in the fourth quarter, despite China’s COVID-19 outbreak that began in December. Revenue for the quarter and full year was CNY 146 billion and CNY 552 billion, respectively, or 4.3% and 6.0% year-on-year growth. Net profit margin for the full year was 1.54%, which shows good margin stability despite a challenging year.